Phase 2Completed
A Study of Enicepatide (CT-388) in Participants Who Are Overweight or Obese With Type 2 Diabetes Mellitus
A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multi-Center Phase 2 Study to Evaluate the Efficacy, Safety, and Tolerability of Once-Weekly CT-388 Administered Subcutaneously for 48 Weeks to Participants Who Are Overweight or Obese With Type 2 Diabetes Mellitus
- Sponsor
- Carmot Therapeutics, Inc. (Industry)
- Enrolment
- 447 enrolled
- Conditions
- Overweight or Obese; Type 2 Diabetes Mellitus (T2DM)
- Interventions
- Placebo; Enicepatide
- Ages
- adults, older adults
- Registry
- NCT06628362
From the registry
This is a multi-center, randomized, double-blind, placebo-controlled, parallel group dose-finding study to evaluate the efficacy and safety of enicepatide at low, middle, and high doses in participants who are overweight or obese with Type 2 diabetes mellitus (T2DM).
Primary outcomes
- Percent Change in Body Weight from Baseline to Week 36
- Change in Glycated Hemoglobin (HbA1c) from Baseline to Week 36